At ExSAR we are passionately dedicated to advancing the identification and development of therapeutic agents through hydrogen/deuterium exchange mass spectrometry technology.
As a service partner, we employ H/D-Exchange to further our clients’ missions and objectives. Clients turn to ExSAR for epitope mapping services in support of therapeutic monoclonal antibody development, and utilize our H/D-Exchange technology to characterize proteins and to identify ligand-binding sites.
As a development-stage company, we’re leveraging our proprietary H/D-Exchange technology to screen lead compounds for their ability to prevent protein misfolding and restore protein function in our quest to identify, develop and commercialize small molecule therapeutics for protein misfolding diseases like Gaucher, Late-Onset Tay Sachs, Sandhoff, ALS and Parkinson’s.
Our understanding and skilled application of this technology has earned us the reputation of being The H/D-Exchange Specialist.